Stefano Brini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefano Brini has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Stanton Newman
School of Health Sciences, City, University of London, London, UK
4 shared publications - Hamid R. Sohrabi
Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA 6150, Australia
3 shared publications Heikki Hämäläinen
Turku Brain and Mind Center, Turku, Finland
3 shared publicationsMira Karrasch
Department of Psychology, Åbo Akademi University, Turku, Finland
3 shared publicationsTimothy J. Fairchild
Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Australia; Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Australia
3 shared publicationsA. Hodkinson
National Institute for Health Research (NIHR), School for Primary Care Research, Manchester Academic Health Science Centre, University of Manchester, United Kingdom
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 2 July 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e92132
Value and Credibility of Meta-Analysis: Tutorial on Enhancing Methodological Rigor and AI-Powered Efficiency
The value of a meta-analysis is based on its methodological and statistical rigor, yet many published systematic reviews and meta-analyses contain statistical shortcomings that limit their utility for clinical practice and public health. This can make it challenging to aggregate data for treatment choices for patients as well as limit the extent to which policymakers can promote social change and improve public health. This challenge is compounded by the traditionally slow and resource-intensive nature of systematic reviews, which delays the translation of vital evidence. In this tutorial, we address both challenges. We first provide a primer on essential statistical techniques to help authors produce more robust and reliable meta-analyses. We then briefly discuss the growing role of artificial intelligence (AI) in automating tasks in systematic literature reviews and meta-analyses. Ethical use and disclosure of AI in supporting these essential tasks are also important considerations. This guide is intended to help authors enhance the rigor of their work and use new technologies to ensure their findings are both trustworthy and timely.
- 2 July 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e92132
Top Cited PapersOpen AccessValue and Credibility of Meta-Analysis: Tutorial on Enhancing Methodological Rigor and AI-Powered Efficiency
The value of a meta-analysis is based on its methodological and statistical rigor, yet many published systematic reviews and meta-analyses contain statistical shortcomings that limit their utility for clinical practice and public health. This can make it challenging to aggregate data for treatment choices for patients as well as limit the extent to which policymakers can promote social change and improve public health. This challenge is compounded by the traditionally slow and resource-intensive nature of systematic reviews, which delays the translation of vital evidence. In this tutorial, we address both challenges. We first provide a primer on essential statistical techniques to help authors produce more robust and reliable meta-analyses. We then briefly discuss the growing role of artificial intelligence (AI) in automating tasks in systematic literature reviews and meta-analyses. Ethical use and disclosure of AI in supporting these essential tasks are also important considerations. This guide is intended to help authors enhance the rigor of their work and use new technologies to ensure their findings are both trustworthy and timely.
- Open Access
- 26 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Value and Credibility of Meta-Analysis: Tutorial on Enhancing Methodological Rigor and AI-Powered Efficiency (Preprint)
UNSTRUCTURED The value of a meta-analysis is based on its methodological and statistical rigor, yet many published systematic reviews and meta-analyses contain statistical shortcomings that limit their utility for clinical practice and public health. This can make it challenging to aggregate data for treatment choices for patients as well as limit the extent to which policymakers can promote social change and improve public health. This challenge is compounded by the traditionally slow and resource-intensive nature of systematic reviews, which delays the translation of vital evidence. In this tutorial, we address both challenges. We first provide a primer on essential statistical techniques to help authors produce more robust and reliable meta-analyses. We then briefly discuss the growing role of artificial intelligence (AI) in automating tasks in systematic literature reviews and meta-analyses. Ethical use and disclosure of AI in supporting these essential tasks are also important considerations. This guide is intended to help authors enhance the rigor of their work and use new technologies to ensure their findings are both trustworthy and timely.
- 26 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessValue and Credibility of Meta-Analysis: Tutorial on Enhancing Methodological Rigor and AI-Powered Efficiency (Preprint)
UNSTRUCTURED The value of a meta-analysis is based on its methodological and statistical rigor, yet many published systematic reviews and meta-analyses contain statistical shortcomings that limit their utility for clinical practice and public health. This can make it challenging to aggregate data for treatment choices for patients as well as limit the extent to which policymakers can promote social change and improve public health. This challenge is compounded by the traditionally slow and resource-intensive nature of systematic reviews, which delays the translation of vital evidence. In this tutorial, we address both challenges. We first provide a primer on essential statistical techniques to help authors produce more robust and reliable meta-analyses. We then briefly discuss the growing role of artificial intelligence (AI) in automating tasks in systematic literature reviews and meta-analyses. Ethical use and disclosure of AI in supporting these essential tasks are also important considerations. This guide is intended to help authors enhance the rigor of their work and use new technologies to ensure their findings are both trustworthy and timely.
- Open Access
- 8 December 2022
- Published by Elsevier in Clinical Psychology Review
- Vol. 100, 102236
Efficacy and safety of transcranial magnetic stimulation for treating major depressive disorder: An umbrella review and re-analysis of published meta-analyses of randomised controlled trials
- 8 December 2022
- Published by Elsevier in Clinical Psychology Review
- Vol. 100, 102236
Open AccessEfficacy and safety of transcranial magnetic stimulation for treating major depressive disorder: An umbrella review and re-analysis of published meta-analyses of randomised controlled trials
- Open Access
- 17 March 2022
- Published by Springer Nature in BMC Neurology
- Vol. 22 (1) , 1-11
A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial
Background: To test, in a two-arm, single center, superiority, randomized controlled trial, the effectiveness of and costs associated with a patient-initiated treatment model for people with hemifacial spasm (HFS) and blepharospasm (BEB) in comparison to usual care.Methods: One hundred and thirty patients with HFS or BEB, aged 18 years or over, were recruited from a nurse-led botulinum toxin type A clinic at an eye hospital in the United Kingdom (UK), completed baseline measures and were randomized (1:1). The intervention group determined their own botulinum toxin type A (BoNT/A) treatment schedule during the trial period (9 months) and received an information leaflet with a “hotline” number to book an appointment. Usual care appointments were scheduled by treating clinicians. Data analysts were blind to study group. The primary outcomes were disease severity and functional disability, as measured by the Jankovic Rating Scale and Blepharospasm Disability Index, respectively. Secondary outcomes included quality of life, anxiety and depression, satisfaction with care, confidence in the service, economic costs and employment days lost.Results: Sixty-five patients were randomized to each group. The intervention demonstrated no statistically significant difference to usual care for any of primary outcomes. On secondary outcomes the levels of anxiety differed significantly (F2, 142.39 = 1.65,p = 0.02), with the intervention arm exhibiting a decrease and the control arm an increase (Hedges’ g = − 0.26 [99% CI -0.83, 0.32]). No other statistically significant differences were found for secondary outcomes. Overall healthcare costs and costs to the patient were on average £198.95 less (95% CI -£256.76, £654.67;p = 0.10) per participant for those in the intervention compared to usual care, although this finding was not significant.Conclusions: We did not observe differences between the patient-initiated treatment model and usual care for people with BEB or HFS, on any primary outcome measure, quality of life, or depression. The patient-initiated treatment model may, however, have the potential to save healthcare costs and reduce anxiety. Patients using this new model were also equally as satisfied in the service and confident in their care as those receiving treatment as usual.Trial registration: Clinicaltrials.gov IDNCT02577224, 16th October 2015.
- 17 March 2022
- Published by Springer Nature in BMC Neurology
- Vol. 22 (1) , 1-11
Open AccessA patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial
Background: To test, in a two-arm, single center, superiority, randomized controlled trial, the effectiveness of and costs associated with a patient-initiated treatment model for people with hemifacial spasm (HFS) and blepharospasm (BEB) in comparison to usual care.Methods: One hundred and thirty patients with HFS or BEB, aged 18 years or over, were recruited from a nurse-led botulinum toxin type A clinic at an eye hospital in the United Kingdom (UK), completed baseline measures and were randomized (1:1). The intervention group determined their own botulinum toxin type A (BoNT/A) treatment schedule during the trial period (9 months) and received an information leaflet with a “hotline” number to book an appointment. Usual care appointments were scheduled by treating clinicians. Data analysts were blind to study group. The primary outcomes were disease severity and functional disability, as measured by the Jankovic Rating Scale and Blepharospasm Disability Index, respectively. Secondary outcomes included quality of life, anxiety and depression, satisfaction with care, confidence in the service, economic costs and employment days lost.Results: Sixty-five patients were randomized to each group. The intervention demonstrated no statistically significant difference to usual care for any of primary outcomes. On secondary outcomes the levels of anxiety differed significantly (F2, 142.39 = 1.65,p = 0.02), with the intervention arm exhibiting a decrease and the control arm an increase (Hedges’ g = − 0.26 [99% CI -0.83, 0.32]). No other statistically significant differences were found for secondary outcomes. Overall healthcare costs and costs to the patient were on average £198.95 less (95% CI -£256.76, £654.67;p = 0.10) per participant for those in the intervention compared to usual care, although this finding was not significant.Conclusions: We did not observe differences between the patient-initiated treatment model and usual care for people with BEB or HFS, on any primary outcome measure, quality of life, or depression. The patient-initiated treatment model may, however, have the potential to save healthcare costs and reduce anxiety. Patients using this new model were also equally as satisfied in the service and confident in their care as those receiving treatment as usual.Trial registration: Clinicaltrials.gov IDNCT02577224, 16th October 2015.
- 1 August 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 291, 384-399
Association of mental disorders with firearm suicides: A systematic review with meta-analyses of observational studies in the United States
- 1 August 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 291, 384-399
Association of mental disorders with firearm suicides: A systematic review with meta-analyses of observational studies in the United States
- 1 March 2021
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 25 (19) , 1-156
Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT
Background: Assistive technology and telecare have been promoted to manage the risks associated with independent living for people with dementia, but there is limited evidence of their effectiveness.Objectives: This trial aimed to establish whether or not assistive technology and telecare assessments and interventions extend the time that people with dementia can continue to live independently at home and whether or not they are cost-effective. Caregiver burden, the quality of life of caregivers and of people with dementia and whether or not assistive technology and telecare reduce safety risks were also investigated.Design: This was a pragmatic, randomised controlled trial. Blinding was not undertaken as it was not feasible to do so. All consenting participants were included in an intention-to-treat analysis.Setting: This trial was set in 12 councils in England with adult social services responsibilities.Participants: Participants were people with dementia living in the community who had an identified need that might benefit from assistive technology and telecare.Interventions: Participants were randomly assigned to receive either assistive technology and telecare recommended by a health or social care professional to meet their assessed needs (a full assistive technology and telecare package) or a pendant alarm, non-monitored smoke and carbon monoxide detectors and a key safe (a basic assistive technology and telecare package).Main outcome measures: The primary outcomes were time to admission to care and cost-effectiveness. Secondary outcomes assessed caregivers using the 10-item Center for Epidemiological Studies Depression Scale, the State–Trait Anxiety Inventory 6-item scale and the Zarit Burden Interview.Results: Of 495 participants, 248 were randomised to receive full assistive technology and telecare and 247 received the limited control. Comparing the assistive technology and telecare group with the control group, the hazard ratio for institutionalisation was 0.76 (95% confidence interval 0.58 to 1.01;p = 0.054). After adjusting for an imbalance in the baseline activities of daily living score between trial arms, the hazard ratio was 0.84 (95% confidence interval 0.63 to 1.12;p = 0.20). At 104 weeks, there were no significant differences between groups in health and social care resource use costs (intervention group – control group difference: mean –£909, 95% confidence interval –£5336 to £3345) or in societal costs (intervention group – control group difference: mean –£3545; 95% confidence interval –£13,914 to £6581). At 104 weeks, based on quality-adjusted life-years derived from the participant-rated EuroQol-5 Dimensions questionnaire, the intervention group had 0.105 (95% confidence interval –0.204 to –0.007) fewer quality-adjusted life-years than the control group. The number of quality-adjusted life-years derived from the proxy-rated EuroQol-5 Dimensions questionnaire did not differ between groups. Caregiver outcomes did not differ between groups over 24 weeks.Limitations: Compliance with the assigned trial arm was variable, as was the quality of assistive technology and telecare needs assessments. Attrition from assessments led to data loss additional to that attributable to care home admission and censoring events.Conclusions: A full package of assistive technology and telecare did not increase the length of time that participants with dementia remained in the community, and nor did it decrease caregiver burden, depression or anxiety, relative to a basic package of assistive technology and telecare. Use of the full assistive technology and telecare package did not increase participants’ health and social care or societal costs. Quality-adjusted life-years based on participants’ EuroQol-5 Dimensions questionnaire responses were reduced in the intervention group compared with the control group; groups did not differ in the number of quality-adjusted life-years based on the proxy-rated EuroQol-5 Dimensions questionnaire.Future work: Future work could examine whether or not improved assessment that is more personalised to an individual is beneficial.Trial registration: Current Controlled Trials ISRCTN86537017.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 25, No. 19. See the NIHR Journals Library website for further project information.
- 1 March 2021
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 25 (19) , 1-156
Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT
Background: Assistive technology and telecare have been promoted to manage the risks associated with independent living for people with dementia, but there is limited evidence of their effectiveness.Objectives: This trial aimed to establish whether or not assistive technology and telecare assessments and interventions extend the time that people with dementia can continue to live independently at home and whether or not they are cost-effective. Caregiver burden, the quality of life of caregivers and of people with dementia and whether or not assistive technology and telecare reduce safety risks were also investigated.Design: This was a pragmatic, randomised controlled trial. Blinding was not undertaken as it was not feasible to do so. All consenting participants were included in an intention-to-treat analysis.Setting: This trial was set in 12 councils in England with adult social services responsibilities.Participants: Participants were people with dementia living in the community who had an identified need that might benefit from assistive technology and telecare.Interventions: Participants were randomly assigned to receive either assistive technology and telecare recommended by a health or social care professional to meet their assessed needs (a full assistive technology and telecare package) or a pendant alarm, non-monitored smoke and carbon monoxide detectors and a key safe (a basic assistive technology and telecare package).Main outcome measures: The primary outcomes were time to admission to care and cost-effectiveness. Secondary outcomes assessed caregivers using the 10-item Center for Epidemiological Studies Depression Scale, the State–Trait Anxiety Inventory 6-item scale and the Zarit Burden Interview.Results: Of 495 participants, 248 were randomised to receive full assistive technology and telecare and 247 received the limited control. Comparing the assistive technology and telecare group with the control group, the hazard ratio for institutionalisation was 0.76 (95% confidence interval 0.58 to 1.01;p = 0.054). After adjusting for an imbalance in the baseline activities of daily living score between trial arms, the hazard ratio was 0.84 (95% confidence interval 0.63 to 1.12;p = 0.20). At 104 weeks, there were no significant differences between groups in health and social care resource use costs (intervention group – control group difference: mean –£909, 95% confidence interval –£5336 to £3345) or in societal costs (intervention group – control group difference: mean –£3545; 95% confidence interval –£13,914 to £6581). At 104 weeks, based on quality-adjusted life-years derived from the participant-rated EuroQol-5 Dimensions questionnaire, the intervention group had 0.105 (95% confidence interval –0.204 to –0.007) fewer quality-adjusted life-years than the control group. The number of quality-adjusted life-years derived from the proxy-rated EuroQol-5 Dimensions questionnaire did not differ between groups. Caregiver outcomes did not differ between groups over 24 weeks.Limitations: Compliance with the assigned trial arm was variable, as was the quality of assistive technology and telecare needs assessments. Attrition from assessments led to data loss additional to that attributable to care home admission and censoring events.Conclusions: A full package of assistive technology and telecare did not increase the length of time that participants with dementia remained in the community, and nor did it decrease caregiver burden, depression or anxiety, relative to a basic package of assistive technology and telecare. Use of the full assistive technology and telecare package did not increase participants’ health and social care or societal costs. Quality-adjusted life-years based on participants’ EuroQol-5 Dimensions questionnaire responses were reduced in the intervention group compared with the control group; groups did not differ in the number of quality-adjusted life-years based on the proxy-rated EuroQol-5 Dimensions questionnaire.Future work: Future work could examine whether or not improved assessment that is more personalised to an individual is beneficial.Trial registration: Current Controlled Trials ISRCTN86537017.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 25, No. 19. See the NIHR Journals Library website for further project information.
- Open Access
- 8 February 2021
- Published by Taylor & Francis in Aging & Mental Health
- Vol. 26 (4) , 709-715
In-home dementia caregiving is associated with greater psychological burden and poorer mental health than out-of-home caregiving: a cross-sectional study
Caregivers who live with a person with dementia who receives care, compared with those who live elsewhere, are often considered to experience greater levels of psychological and affective burden. T...
- 8 February 2021
- Published by Taylor & Francis in Aging & Mental Health
- Vol. 26 (4) , 709-715
Open AccessIn-home dementia caregiving is associated with greater psychological burden and poorer mental health than out-of-home caregiving: a cross-sectional study
Caregivers who live with a person with dementia who receives care, compared with those who live elsewhere, are often considered to experience greater levels of psychological and affective burden. T...
- 18 April 2020
- Published by Wiley in British Journal of Health Psychology
- Vol. 25 (3) , 405-427
Associations between health literacy and health care utilization and mortality in patients with coexisting diabetes and end‐stage renal disease: A prospective cohort study
Objectives: Health literacy encompasses a broad skill set linked to patients' self‐management ability and the complexity of their health care environments. Self‐management in the context of multimorbidity is particularly challenging, placing patients at risk of poor clinical outcomes. This study aimed to explore the prognostic associations between health literacy domains, depression, and 12‐month health care utilization and mortality in patients with diabetes and end‐stage renal disease (DM‐ESRD). Design: Observational study. Methods: Patients with DM‐ESRD undergoing haemodialysis were recruited. Information on all‐cause hospitalization/admission and mortality of participants was recorded. Negative binomial and Cox regressions were used to model risk factors for hospitalization and mortality. Results: A total 221 participants [median age: 59 years, 61.6% men, 54.8% Chinese] were recruited. Differences in health literacy were found as a function of age, ethnicity, relationship status, and education. After adjusting for demographic and clinical factors, the HLQ domain Actively Managing My Health remained independently associated with lower rates of hospitalization (incidence rate ratio (IRR) = 0.674, 95% CI [0.490, 0.925], p = .02) and mortality (hazard ratio = 0.382, 95% CI [0.160, 0.848], p = .02). Cumulative hospitalization days were associated with employment status (IRR = 2.242, 95% CI [1.223, 4.113], p = .009), albumin (IRR = 0.918, 95% CI [0.854, 0.988], p = .02), HbA1c (IRR = 1.183, 95% CI [1.028, 1.360], p = .02), comorbidity burden (IRR = 1.137, 95% CI [1.003, 1.289], p = .04), and depression (IRR = 1.059, 95% CI [1.003, 1.118], p = .04) but no health literacy domains. Conclusions: Health literacy skills related to Actively Managing My Health predict hospitalization and mortality independently of other risk factors. The HLQ provides an assessement of novel health literacy parameters which offer new insights into patients’ status and behaviours and may strengthen interventions to improve clinical services, and patient outcomes in DM‐ESRD. Statement of contribution: What is already known on this subject? Patients with diabetes (DM) comprise the fastest growing segment of patients with end‐stage renal disease (ESRD). Health literacy (HL) is pivotal for managing the complex treatment guidelines for DM‐ESRD. Most prior work on HL focused on functional HL and shown significant associations with mortality and hospitalization. Limited research has investigated wider HL skills in relation to clinical outcomes. What does this study add? Supporting patients in Actively Managing my health liteacy skills is critical in decreasing probability of hospitalization and morbidity. The presence of symptoms of depression is associated with longer hospitalization period.
- 18 April 2020
- Published by Wiley in British Journal of Health Psychology
- Vol. 25 (3) , 405-427
Associations between health literacy and health care utilization and mortality in patients with coexisting diabetes and end‐stage renal disease: A prospective cohort study
Objectives: Health literacy encompasses a broad skill set linked to patients' self‐management ability and the complexity of their health care environments. Self‐management in the context of multimorbidity is particularly challenging, placing patients at risk of poor clinical outcomes. This study aimed to explore the prognostic associations between health literacy domains, depression, and 12‐month health care utilization and mortality in patients with diabetes and end‐stage renal disease (DM‐ESRD). Design: Observational study. Methods: Patients with DM‐ESRD undergoing haemodialysis were recruited. Information on all‐cause hospitalization/admission and mortality of participants was recorded. Negative binomial and Cox regressions were used to model risk factors for hospitalization and mortality. Results: A total 221 participants [median age: 59 years, 61.6% men, 54.8% Chinese] were recruited. Differences in health literacy were found as a function of age, ethnicity, relationship status, and education. After adjusting for demographic and clinical factors, the HLQ domain Actively Managing My Health remained independently associated with lower rates of hospitalization (incidence rate ratio (IRR) = 0.674, 95% CI [0.490, 0.925], p = .02) and mortality (hazard ratio = 0.382, 95% CI [0.160, 0.848], p = .02). Cumulative hospitalization days were associated with employment status (IRR = 2.242, 95% CI [1.223, 4.113], p = .009), albumin (IRR = 0.918, 95% CI [0.854, 0.988], p = .02), HbA1c (IRR = 1.183, 95% CI [1.028, 1.360], p = .02), comorbidity burden (IRR = 1.137, 95% CI [1.003, 1.289], p = .04), and depression (IRR = 1.059, 95% CI [1.003, 1.118], p = .04) but no health literacy domains. Conclusions: Health literacy skills related to Actively Managing My Health predict hospitalization and mortality independently of other risk factors. The HLQ provides an assessement of novel health literacy parameters which offer new insights into patients’ status and behaviours and may strengthen interventions to improve clinical services, and patient outcomes in DM‐ESRD. Statement of contribution: What is already known on this subject? Patients with diabetes (DM) comprise the fastest growing segment of patients with end‐stage renal disease (ESRD). Health literacy (HL) is pivotal for managing the complex treatment guidelines for DM‐ESRD. Most prior work on HL focused on functional HL and shown significant associations with mortality and hospitalization. Limited research has investigated wider HL skills in relation to clinical outcomes. What does this study add? Supporting patients in Actively Managing my health liteacy skills is critical in decreasing probability of hospitalization and morbidity. The presence of symptoms of depression is associated with longer hospitalization period.
- Open Access
- 13 March 2020
- Published by Springer Nature in Neuropsychology Review
- Vol. 30 (1) , 25-27
Correction to: Bilingualism Is Associated with a Delayed Onset of Dementia but Not with a Lower Risk of Developing it: a Systematic Review with Meta-Analyses
The original version of this article unfortunately contained the following mistakes.
- 13 March 2020
- Published by Springer Nature in Neuropsychology Review
- Vol. 30 (1) , 25-27
Open AccessCorrection to: Bilingualism Is Associated with a Delayed Onset of Dementia but Not with a Lower Risk of Developing it: a Systematic Review with Meta-Analyses
The original version of this article unfortunately contained the following mistakes.